AMBRISENTAN TAB
Clinical Criteria Summary
Exclusion Criteria
- Known pregnancy
- Moderate or severe liver impairment (e.g., Child-Pugh Class B or C)
Inclusion Criteria
- Care provided by a VA/VA Community Care provider experienced in the management of pulmonary arterial hypertension (PAH)
- World Health Organization (WHO) Group 1 PAH
- Definitive PAH confirmed by right-heart catheterization and hemodynamic diagnosis: mean pulmonary artery pressure >25 mmHg, pulmonary artery wedge pressure ≤15 mm Hg, and pulmonary vascular resistance >3 Wood Units
Additional Inclusion Criteria
- Females who can become pregnant: Excluded pregnancy prior to receiving ambrisentan. Provided counseling on potential risk vs benefit of treatment and use of effective contraception prior to, during, and one month after stopping treatment.
- For males of reproductive potential: Counseling provided on the potential risk of ambrisentan to adversely affect spermatogenesis and impair fertility.